Methotrexate, the active ingredient of Methotrexate tablets, is an antimetabolite used as a disease-modifying antirheumatic drug for selected inflammatory, autoimmune and oncological conditions. It reduces abnormal immune activity and slows excessive cell growth, which can ease inflammatory disease activity when it is prescribed and monitored correctly.
Methotrexate belongs to two important medicine groups: antimetabolites and immunosuppressants. In rheumatology, it is classed among Disease-Modifying Antirheumatic Drugs, often shortened to DMARDs. The tablets contain methotrexate as the active substance. Methotrexate can also be used in injectable clinical formulations when a prescriber considers that route appropriate. Tablet treatment is used for selected patients when oral therapy suits the treatment plan.
The tablets contain methotrexate as the active substance. Methotrexate can also be used in injectable clinical formulations when a prescriber considers that route appropriate. Tablet treatment is used for selected patients when oral therapy suits the treatment plan.
Methotrexate interferes with folate-dependent processes in cells. Folate is a B-vitamin nutrient involved in making DNA and supporting normal cell division. This action explains both its therapeutic role and the need for careful monitoring.
Methotrexate competitively inhibits dihydrofolate reductase, an enzyme involved in recycling folate for folate-dependent DNA synthesis. Cells that divide quickly depend heavily on this pathway. Reducing that activity can limit abnormal cell replication in cancer treatment.
At the lower doses used in inflammatory disease, its benefit is not explained only by DNA synthesis. Methotrexate also increases extracellular adenosine, a signalling molecule that helps dampen inflammatory immune activity. This is why its role in rheumatoid arthritis and psoriasis differs from its role in cancer care.
The effect builds gradually. It does not work like a painkiller taken for same-day relief. In clinical practice, clinicians assess trends in joint swelling, morning stiffness, skin inflammation, blood results and function over repeated reviews rather than judging treatment from a single good or bad day.
Methotrexate is a foundational treatment in rheumatology and dermatology. It may be prescribed for rheumatoid arthritis, psoriatic arthritis, severe plaque psoriasis and certain other immune-mediated disorders. It can reduce swollen joints, improve physical function and help limit progressive inflammatory damage when the condition responds.
NICE places conventional DMARDs, including methotrexate, at the centre of treatment strategies for active rheumatoid arthritis [2]. For psoriasis, treatment decisions reflect the severity and extent of skin disease, other health conditions and prior treatment response.
Methotrexate is also used in cancer treatments, where its antimetabolite effect is used to slow the growth of malignant cells. High-dose methotrexate is a hospital-based treatment approach and differs greatly from tablet regimens used for autoimmune or inflammatory disease.
High-dose treatment may involve intravenous administration, intensive fluid management, kidney-function testing and timed folinic acid rescue. Folinic acid rescue protects healthy cells after methotrexate exposure while allowing the intended anti-cancer action to occur. It is managed by oncology teams with protocol-based monitoring.
The WHO Model List of Essential Medicines includes methotrexate for specific indications, reflecting its established place in both oncology and immune-mediated disease care [4]. A tablet prescribed for chronic inflammatory disease must never be treated as equivalent to a hospital oncology regimen.
Significant bone marrow suppression.
Severe active liver disease.
Clinically significant infection unless the prescriber managing the condition gives clear instructions.
Impaired kidney function requires extra caution because methotrexate is cleared through the kidneys.
Trimethoprim and co-trimoxazole are major examples because they can increase the risk of severe bone marrow suppression.
The EMA advises ongoing monitoring for blood-cell, liver and kidney effects during methotrexate treatment [3].
Methotrexate is not for you if you are pregnant, are trying to conceive without a specialist plan, are breastfeeding, have significant bone marrow suppression, or have severe active liver disease. It is also unsuitable during clinically significant infection unless the prescriber managing the condition gives clear instructions.
Nausea, reduced appetite, tiredness, mouth soreness and headache can occur with Methotrexate tablets. Some people feel washed out on the day after their weekly dose. Hair thinning may occur, though marked hair loss is less common with the low-dose regimens used for inflammatory disease.
Liver irritation and bone marrow suppression are the major safety concerns. Bone marrow suppression means the body produces too few blood cells, which can lead to infection, bruising, bleeding or anaemia. Liver effects may be silent at first, so blood tests remain necessary even when a person feels well.
Seek urgent medical assessment for fever, chills, a persistent sore throat, mouth ulcers with feeling unwell, unusual bruising, black stools, severe breathlessness, yellowing of the eyes or skin, or a widespread blistering rash. These symptoms can signal infection, low blood counts, bleeding or organ toxicity.
Extra caution is needed with impaired kidney function because methotrexate is cleared through the kidneys. Dehydration, vomiting, diarrhoea and acute illness can reduce clearance and raise blood levels. Heavy alcohol use adds liver risk.
Several medicines can alter methotrexate safety. Trimethoprim and co-trimoxazole are major examples because they can increase the risk of severe bone marrow suppression. Non-steroidal anti-inflammatory drugs, some antibiotics, proton-pump inhibitors and medicines that affect kidney function may also require review.
| Treatment approach | Main role | Key limitation |
|---|---|---|
| Methotrexate | Systemic DMARD that modifies inflammatory disease activity | Requires regular blood monitoring and weekly dosing |
| Sulfasalazine | Conventional DMARD for inflammatory arthritis | May cause gastrointestinal effects, rash or blood-count changes |
| Corticosteroids | Short-term control of inflammation or flare symptoms | Long-term use can cause substantial metabolic and bone effects |
Methotrexate and sulfasalazine may be used alone or as part of a specialist-led DMARD plan. Corticosteroids can settle symptoms faster, yet they do not replace a long-term disease-modifying strategy. Azathioprine may be used for selected immune-mediated conditions, though it has a different monitoring profile and is not interchangeable with methotrexate.
In clinical practice, doctors often describe methotrexate as an anchor DMARD: it is familiar, useful for many inflammatory conditions and can be combined with selected treatments when required. They also stress that success depends on the correct weekly schedule, planned blood tests and early reporting of infection or toxicity symptoms.
A useful expectation is gradual improvement rather than an immediate switch in symptoms. If nausea occurs, clinicians may adjust folic acid, alter the timing, review other medicines or consider a different route of administration. Persistent abnormal blood results or troublesome adverse effects need prompt review rather than repeated self-adjustment.
Methotrexate is designed for a weekly treatment schedule in many inflammatory conditions, but its clinical effect is cumulative rather than limited to a single day. The medicine remains active in cells beyond the day it is taken, while disease control develops through consistent treatment over time. The exact schedule depends on the condition and prescribed regimen. The MHRA’s 2020 safety communication reinforces the weekly dosing principle because incorrect daily administration can be dangerous. [1]
Regular blood-test attendance, keeping the same weekly dosing day and maintaining good hydration can support safer treatment. Heavy alcohol intake can raise concern about liver toxicity, especially where liver tests are already abnormal. Smoking cessation, gradual physical activity and weight management may help joint function or psoriasis severity, though they do not replace DMARD treatment. NICE guidance from 2020 supports structured disease management in rheumatoid arthritis.
Alcohol needs an individual discussion because both alcohol and methotrexate can affect the liver. People with liver disease, abnormal liver tests or heavy alcohol intake face higher concern. The EMA’s 2019 methotrexate product information advises attention to liver function and risk factors during treatment. Avoiding binge drinking is a sensible minimum precaution.
Older adults can use Methotrexate when it is clinically appropriate, though kidney function, other medicines and frailty need closer review. Reduced kidney clearance can increase exposure and toxicity risk. The MHRA’s 2020 safety guidance advises careful use where dosing errors or interacting medicines are possible, which can be more common with complex medication schedules. Prescribers may monitor blood results more closely after changes in health status.
Some antibiotics are compatible, while trimethoprim and co-trimoxazole can be dangerous with Methotrexate because of the risk of serious blood-cell suppression. The British National Formulary’s 2020 guidance flagged this interaction, and clinicians usually choose an alternative antibiotic where possible. Always identify Methotrexate as part of your current treatment when an antibiotic is being considered. Do not assume an antibiotic used safely in the past remains suitable now.
Methotrexate can cause tiredness, dizziness, headache or a general unwell feeling in some people. These effects may be more noticeable on the dose day or the following day. The EMA’s 2019 product information advises caution with activities requiring alertness if such symptoms occur. Plan demanding driving or machinery tasks around your established individual response where possible.
Methotrexate may be prescribed to children and adolescents for selected conditions by paediatric specialist teams. The condition being treated, body size, kidney function and monitoring needs shape the regimen. WHO’s 2023 materials recognise methotrexate’s use in specialist care, while paediatric dosing requires a prescriber experienced in that setting. A child must never receive an adult’s tablets or follow an adult treatment schedule.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took my weekly tablets on Sunday evenings for several months. The nausea was annoying at first, and I felt tired the next day, but my hands were much less stiff by later follow-up appointments. Folic acid made the mouth soreness easier to manage.
The improvement was gradual rather than dramatic. I noticed fewer sore patches and less scaling after regular use, but I had to arrange blood tests around work. Missing an appointment made me realise how much organisation this treatment needs.
I stopped taking my tablets for a short time when I had a chest infection, then contacted my clinic before restarting. The hardest part was remembering it was weekly, not daily. A phone reminder solved that.
I found the day after my dose difficult because I felt queasy and tired. My skin improved, but the side effects did not settle enough for me, so my specialist reviewed the plan and changed the approach.
